Publications

Top
Publications

 2025  

Rocha P, Bach R, Masfarr�� L, Hernandez S, Navarro-Gorro N, Rossell A, Villanueva X, Giner M, Sanch��z I, Galindo M, Del Rey-Vergara R, I?a?ez A, Sanch��z-Espiridion B, Lu W, Acedo-Terrades A, Berenguer-Molins P, S��nchez-Font A, Chalela R, Curull V, Taus ?, Hardy-Werbin M, Sausen M, Georgiadis A, White J, Jackson JB, Moliner L, Clav�� S, Bellosillo B, Rovira A, Wistuba I, Soto LMS, Perera-Bel J, Arriola E. Molecular and immunological features associated with long-term benefits in metastatic NSCLC patients undergoing immune checkpoint blockade. Oncoimmunology. 14(1):2469377 (2025).
Kowash RR, Sabnani M, Gray LT, Deng Q, Saleh NUA, Girard L, Naito Y, Masahiro K, Minna JD, Gerber DE, Koyama S, Liu ZL, Baruah H, Akbay EA. Novel and potent MICA/B antibody is therapeutically effective in KRAS LKB1 mutant lung cancer models. J Immunother Cancer. 13(1):e009867 (2025).
Zhou Y, Xiao X, Dong L, Tang C, Xiao G, Xu L. Cooperative integration of spatially resolved multi-omics data with COSMOS. Nat Commun. 16(1):27 (2025).
von Itzstein MS, Burns TF, Dowell JE, Horn L, Camidge DR, York SJ, Eaton KD, Kyle K, Fattah F, Liu J, Mu-Mosley H, Gupta A, Nadeem U, Gao A, Zhang S, Gerber DE. Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 31(4):639-648 (2025).

 2024  

Song X, Zhou Z, Elmezayen A, Wu R, Yu C, Gao B, Minna JD, Westover KD, Zeh HJ, Kroemer G, Heasley LE, Kang R, Tang D. SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition. Sci Adv. 10(50) (2024).
von Itzstein MS, Liu J, Mu-Mosley H, Fattah F, Park JY, SoRelle JA, Farrar JD, Gwin ME, Hsiehchen D, Gloria-McCutchen Y, Wakeland EK, Cole S, Bhalla S, Kainthla R, Puzanov I, Switzer B, Daniels GA, Zakharia Y, Shaheen M, Zhang J, Xie Y, Gerber DE. Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer. JTO Clin Res Rep. 6(1):100751 (2024).
Serrano AG, Rocha P, Freitas Lima C, Stewart A, Zhang B, Diao L, Fujimoto J, Cardnell RJ, Lu W, Khan K, Sable B, Ellison AR, Wistuba II, Concannon KF, Halperin DM, Bogdan C, Sircar K, Zhang M, Cargill K, Wang Q, Aparicio A, Lazar A, Hernandez S, Estrella J, Ramalingam P, El-Naggar A, Kalhor N, Gay CM, Byers LA, Solis Soto LM. Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms. NPJ Precis Oncol. 8(1):268 (2024).
Hong L, Patel S, Drusbosky LM, Xiong Y, Chen R, Geng R, Heeke S, Nilsson M, Wu J, Heymach JV, Wang Y, Zhang J, Le X. Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients. NPJ Precis Oncol. 8(1):217 (2024). 
Martin-Vega A, Earnest SA, Augustyn A, Wichaidit C, Girard L, Peyton M, Minna JD, Johnson JE, Cobb MH. ASCL1 Restrains ERK1/2 to Promote Survival of a Subset of Neuroendocrine Lung Cancers. Mol Cancer Ther. 23(12):1789-1800 (2024).
Germain A, Sabol A, Chavali A, Fitzwilliams G, Cooper A, Khuon S, Green B, Kong C, Minna J, Kim YT. Machine learning enabled classification of lung cancer cell lines co-cultured with fibroblasts with lightweight convolutional neural network for initial diagnosis. J Biomed Sci. 31(1):84 (2024).
Nguyen A, Nu?ez CG, Tran TA, Girard L, Peyton M, Catalan R, Guerena C, Avila K, Drapkin BJ, Chandra R, Minna JD, Martinez ED. Jumonji histone demethylases are therapeutic targets in small cell lung cancer. Oncogene. 43(38):2885-2899 (2024).
Stewart CA, Diao L, Xi Y, Wang R, Ramkumar K, Serrano AG, Tanimoto A, Rodriguez BL, Morris BB, Shen L, Zhang B, Yang Y, Hamad SH, Cardnell RJ, Duarte A Jr, Sahu M, Novegil VY, Weissman BE, Frumovitz M, Kalhor N, Solis Soto L, da Rocha P, Vokes N, Gibbons DL, Wang J, Heymach JV, Glisson B, Byers LA, Gay CM. YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities. Clin Cancer Res. 30(20):4743-4754 (2024).
on Itzstein MS, Gerber DE, Bermas BL, Meara A. Acknowledging and addressing real-world challenges to treating immune-related adverse events. J Immunother Cancer. 12(7):e009540 (2024).
Hyder U, Challa A, Thornton M, Nandu T, Kraus WL, D'Orso I. KAP1 negatively regulates RNA polymerase II elongation kinetics to activate signal-induced transcription. Nat Commun. 15(1):5859 (2024).
Lee HM, Muhammad N, Lieu EL, Cai F, Mu J, Ha YS, Cao G, Suchors C, Joves K, Chronis C, Li K, Ducker GS, Olszewski K, Cai L, Allison DB, Bachert SE, Ewing WR, Wong H, Seo H, Kim IY, Faubert B, Kim J, Kim J. Concurrent loss of LKB1 and KEAP1 enhances SHMT-mediated antioxidant defence in KRAS-mutant lung cancer. Nat Metab. 6(7):1310-1328 (2024). 
Wu Z, Bezwada D, Cai F, Harris RC, Ko B, Sondhi V, Pan C, Vu HS, Nguyen PT, Faubert B, Cai L, Chen H, Martin-Sandoval M, Do D, Gu W, Zhang Y, Zhang Y, Brooks B, Kelekar S, Zacharias LG, Oaxaca KC, Patricio JS, Mathews TP, Garcia-Bermudez J, Ni M, DeBerardinis RJ. Electron transport chain inhibition increases cellular dependence on purine transport and salvage. Cell Metab. 36(7):1504-1520 (2024).
Wang X, Menezes CJ, Jia Y, Xiao Y, Venigalla SSK, Cai F, Hsieh MH, Gu W, Du L, Sudderth J, Kim D, Shelton SD, Llamas CB, Lin YH, Zhu M, Merchant S, Bezwada D, Kelekar S, Zacharias LG, Mathews TP, Hoxhaj G, Wynn RM, Tambar UK, DeBerardinis RJ, Zhu H, Mishra P. Metabolic inflexibility promotes mitochondrial health during liver regeneration. Science. 384(6701):eadj4301 (2024).
Sunil HS, O'Donnell KA. Capturing heterogeneity in PDX models: representation matters. Nat Commun. 15(1):4652 (2024). 
Konen JM, Wu H, Gibbons DL. Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities. Trends Pharmacol Sci. 45(6):520-536 (2024). 
Mu-Mosley H, von Itzstein MS, Fattah F, Liu J, Zhu C, Xie Y, Wakeland EK, Park JY, Kahl BS, Diefenbach CS, Gerber DE. Distinct autoantibody profiles across checkpoint inhibitor types and toxicities. Oncoimmunology. 13(1):2351255 (2024). 
Wang Y, Flowers CR, Wang M, Huang X, Li Z. CASi: A framework for cross-timepoint analysis of single-cell RNA sequencing data. Sci Rep. 14(1):10633 (2024). 
Huang J, Yang DM, Rong R, Nezafati K, Treager C, Chi Z, Wang S, Cheng X, Guo Y, Klesse LJ, Xiao G, Peterson ED, Zhan X, Xie Y. A critical assessment of using ChatGPT for extracting structured data from clinical notes. NPJ Digit Med. 7(1):106 (2024).
von Itzstein MS, Yang Y, Wang Y, Hsiehchen D, Sheffield TY, Fattah F, Popat V, Ahmed M, Homsi J, Dowell JE, Rashdan S, Lohrey J, Hammers HJ, Hughes RS, Wang T, Xie Y, Gerber DE. Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice. Front Immunol. 15:1351739 (2024). 
Rodriguez BL, Huang J, Gibson L, Fradette JJ, Chen HH, Koyano K, Cortez C, Li B, Ho C, Ashique AM, Lin VY, Crawley S, Roda JM, Chen P, Fan B, Kim J, Sissons J, Sitrin J, Kaplan DD, Gibbons DL, Rivera LB. Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors. Mol Cancer Ther. 23(8):1144-1158 (2024).
Makio T, Zhang K, Love N, Mast FD, Liu X, Elaish M, Hobman T, Aitchison JD, Fontoura BMA, Wozniak RW. SARS-CoV-2 Orf6 is positioned in the nuclear pore complex by Rae1 to inhibit nucleocytoplasmic transport. Mol Biol Cell. 35(5):ar62 (2024).
Han G, Sinjab A, Rahal Z, Lynch AM, Treekitkarnmongkol W, Liu Y, Serrano AG, Feng J, Liang K, Khan K, Lu W, Hernandez SD, Liu Y, Cao X, Dai E, Pei G, Hu J, Abaya C, Gomez-Bolanos LI, Peng F, Chen M, Parra ER, Cascone T, Sepesi B, Moghaddam SJ, Scheet P, Negrao MV, Heymach JV, Li M, Dubinett SM, Stevenson CS, Spira AE, Fujimoto J, Solis LM, Wistuba II, Chen J, Wang L, Kadara H. An atlas of epithelial cell states and plasticity in lung adenocarcinoma. Nature. 627(8004):656-663 (2024). 
Pal Choudhuri S, Girard L, Lim JYS, Wise JF, Freitas B, Yang D, Wong E, Hamilton S, Chien VD, Kim YJ, Gilbreath C, Zhong J, Phat S, Myers DT, Christensen CL, Mazloom-Farsibaf H, Stanzione M, Wong KK, Hung YP, Farago AF, Meador CB, Dyson NJ, Lawrence MS, Wu S, Drapkin BJ. Acquired Cross-Resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC Paralogs. Cancer Discov. 14(5):804-827 (2024).
Zhang B, Lewis W, Stewart CA, Morris BB, Solis LM, Serrano A, Xi Y, Wang Q, Lopez ER, Concannon K, Heeke S, Tang X, Raso G, Cardnell RJ, Vokes N, Blumenschein G, Elamin Y, Fosella F, Tsao A, Skoulidis F, Hume CB, Sasak K, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Tran H, Zhang J, Gibbons D, Vaporciyan A, Wang J, Park K, Heymach JV, Byers LA, Gay CM, Le X. Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets. JTO Clin Res Rep. 5(2):100623 (2024). 
Heeke S, Gay CM, Estecio MR, Tran H, Morris BB, Zhang B, Tang X, Raso MG, Rocha P, Lai S, Arriola E, Hofman P, Hofman V, Kopparapu P, Lovly CM, Concannon K, De Sousa LG, Lewis WE, Kondo K, Hu X, Tanimoto A, Vokes NI, Nilsson MB, Stewart A, Jansen M, Horv��th I, Gaga M, Panagoulias V, Raviv Y, Frumkin D, Wasserstrom A, Shuali A, Schnabel CA, Xi Y, Diao L, Wang Q, Zhang J, Van Loo P, Wang J, Wistuba II, Byers LA, Heymach JV. Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. Cancer Cell. 42(2):225-237.e5 (2024)
Eglenen-Polat B, Kowash RR, Huang HC, Siteni S, Zhu M, Chen K, Bender ME, Mender I, Stastny V, Drapkin BJ, Raj P, Minna JD, Xu L, Shay JW, Akbay EA. A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer. Nat Commun. 15(1):672 (2024). 
Kim C, Wang XD, Liu Z, Hao J, Wang S, Li P, Zi Z, Ding Q, Jang S, Kim J, Luo Y, Huffman KE, Pal Choudhuri S, Del Rio S, Cai L, Liang H, Drapkin BJ, Minna JD, Yu Y. Induced degradation of lineage-specific oncoproteins drives the therapeutic vulnerability of small cell lung cancer to PARP inhibitors. Sci Adv. 10(3):eadh2579 (2024). 
Chen H, Drapkin BJ, Minna JD. Proteomics: A new dimension to decode small cell lung cancer. Cell. 187(1):14-16 (2024).
Ng J, Cai L, Girard L, Prall OWJ, Rajan N, Khoo C, Batrouney A, Byrne DJ, Boyd DK, Kersbergen AJ, Christie M, Minna JD, Burr ML, Sutherland KD. Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies. Clin Cancer Res. 30(9):1846-1858 (2024). 
Wen Z, Luo D, Wang S, Rong R, Evers BM, Jia L, Fang Y, Daoud EV, Yang S, Gu Z, Arner EN, Lewis CM, Solis Soto LM, Fujimoto J, Behrens C, Wistuba II, Yang DM, Brekken RA, O'Donnell KA, Xie Y, Xiao G. Deep Learning-Based H-Score Quantification of Immunohistochemistry-Stained Images. Mod Pathol. 37(2):100398 (2024). 
Sunaga N, Kaira K, Shimizu K, Tanaka I, Miura Y, Nakazawa S, Ohtaki Y, Kawabata-Iwakawa R, Sato M, Girard L, Minna JD, Hisada T. The oncogenic role of LGR6 overexpression induced by aberrant Wnt/��-catenin signaling in lung cancer. Thorac Cancer. 15(2):131-141 (2024). 
Wang K, Du R, Myall NJ, Lewis WE, Uy N, Hong L, Skoulidis F, Byers LA, Tsao A, Cascone T, Pozadzides J, Tu J, Negrao MV, Gibbons DL, Park K, Rinsurongkawong W, Lee JJ, Gandara D, Behl D, Shu CA, Riess JW, Baik C, Wakelee HA, Vaporciyan AA, Heymach JV, Zhang J, Le X. Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. J Thorac Oncol. 19(3):500-506 (2024). 

 2023  

Parra, E. R., Zhang, J., Jiang, M., Tamegnon, A., Pandurengan, R. K., Behrens, C., Solis, L., Haymaker, C., Heymach, J. V., Moran, C., Lee, J. J., Gibbons, D. & Wistuba, I. I. Immune cellular patterns of distribution affect outcomes of patients with non-small cell lung cancer. Nat. Commun. 14, 2364 (2023).
Iyengar, P., Gandhi, A. Y., Granados, J., Guo, T., Gupta, A., Yu, J., Llano, E. M., Zhang, F., Gao, A., Kandathil, A., Williams, D., Gao, B., Girard, L., Malladi, V. S., Shelton, J. M., Evers, B. M., Hannan, R., Ahn, C., Minna, J. D. & Infante, R. E. Tumor loss-of-function mutations in STK11/LKB1 induce cachexia. JCI Insight 8, (2023).
Patel, S. A., Nilsson, M. B., Yang, Y., Le, X., Tran, H. T., Elamin, Y. Y., Yu, X., Zhang, F., Poteete, A., Ren, X., Shen, L., Wang, J., Moghaddam, S. J., Cascone, T., Curran, M., Gibbons, D. L. & Heymach, J. V. IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC. Clin. Cancer Res. 29, 1292�C1304 (2023).
Concannon, K., Morris, B. B., Gay, C. M. & Byers, L. A. Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control. Mol. Cell 83, 660�C680 (2023).
Kim, J. & Minna, J. D. Moving toward precision medicine with lung cancer organoids. Cell Rep. Med. 4, 100952 (2023).
Wang, S., Rong, R., Yang, D. M., Fujimoto, J., Bishop, J. A., Yan, S., Cai, L., Behrens, C., Berry, L. D., Wilhelm, C., Aisner, D., Sholl, L., Johnson, B. E., Kwiatkowski, D. J., Wistuba, I. I., Bunn, P. A., Minna, J., Xiao, G., Kris, M. G. & Xie, Y. Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer. J. Clin. Invest. 133, (2023).
Patel, S. A., Nilsson, M. B., Le, X., Cascone, T., Jain, R. K. & Heymach, J. V. Molecular mechanisms and future implications of VEGF/VEGFR in cancer therapy. Clin. Cancer Res. 29, 30�C39 (2023).
Sun, B., Laberiano-Fern��ndez, C., Salazar-Alejo, R., Zhang, J., Solorzano Rendon, J. L., Lee, J., Solis Soto, L. M., Wistuba, I. I. & Parra, E. R. Impact of Region-of-Interest Size on Immune Profiling Using Multiplex Immunofluorescence Tyramide Signal Amplification for Paraffin-Embedded Tumor Tissues. Pathobiology 90, 1�C12 (2023).
Huffman, K. E., Li, L. S., Carstens, R., Park, H., Girard, L., Avila, K., Wei, S., Kollipara, R., Timmons, B., Sudderth, J., Bendris, N., Kim, J., Villalobos, P., Fujimoto, J., Schmid, S., Deberardinis, R. J., Wistuba, I., Heymach, J., Kittler, R., Akbay, E. A., Posner, B., Wang, Y., Lam, S., Kliewer, S. A., Mangelsdorf, D. J. & Minna, J. D. Glucocorticoid mediated inhibition of LKB1 mutant non-small cell lung cancers. Front. Oncol. 13, 1025443 (2023).

 2022  

Pongor, L. S., Tlemsani, C., Elloumi, F., Arakawa, Y., Jo, U., Gross, J. M., Mosavarpour, S., Varma, S., Kollipara, R. K., Roper, N., Teicher, B. A., Aladjem, M. I., Reinhold, W., Thomas, A., Minna, J. D., Johnson, J. E. & Pommier, Y. Integrative epigenomic analyses of small cell lung cancer cells demonstrates the clinical translational relevance of gene body methylation. iScience 25, 105338 (2022).

Park, J. V., Chandra, R., Cai, L., Ganguly, D., Li, H., Toombs, J. E., Girard, L., Brekken, R. A. & Minna, J. D. Tumor Cells Modulate Macrophage Phenotype in a Novel In Vitro Co-Culture Model of the NSCLC Tumor Microenvironment. J. Thorac. Oncol. 17, 1178�C1191 (2022).
Moore, C., Bae, J., Liu, L., Li, H., Fu, Y.-X. & Qiao, J. Exogenous signaling repairs defective T cell signaling inside the tumor microenvironment for better immunity. JCI Insight 7, (2022).
Pachnis, P., Wu, Z., Faubert, B., Tasdogan, A., Gu, W., Shelton, S., Solmonson, A., Rao, A. D., Kaushik, A. K., Rogers, T. J., Ubellacker, J. M., LaVigne, C. A., Yang, C., Ko, B., Ramesh, V., Sudderth, J., Zacharias, L. G., Martin-Sandoval, M. S., Do, D., Mathews, T. P., Zhao, Z., Mishra, P., Morrison, S. J. & DeBerardinis, R. J. In vivo isotope tracing reveals a requirement for the electron transport chain in glucose and glutamine metabolism by tumors. Sci. Adv. 8, eabn9550 (2022).
Kelenis, D. P., Rodarte, K. E., Kollipara, R. K., Pozo, K., Choudhuri, S. P., Spainhower, K. B., Wait, S. J., Stastny, V., Oliver, T. G. & Johnson, J. E. Inhibition of Karyopherin ��1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer. Cancer Res. 82, 3058�C3073 (2022).
Cai, L., DeBerardinis, R. J., Xiao, G., Minna, J. D. & Xie, Y. A Pan-Cancer Assessment of RB1/TP53 Co-Mutations. Cancers (Basel) 14, (2022).
Terajima, M., Taga, Y., Nakamura, T., Guo, H.-F., Kayashima, Y., Maeda-Smithies, N., Parag-Sharma, K., Kim, J. S., Amelio, A. L., Mizuno, K., Kurie, J. M. & Yamauchi, M. Lysyl hydroxylase 2 mediated collagen post-translational modifications and functional outcomes. Sci. Rep. 12, 14256 (2022).
von Itzstein, M. S., Gerber, D. E. & Minna, J. D. Circulating mitochondrial DNA as a biomarker for lung cancer screening. Transl. Lung Cancer Res. 11, 1522�C1525 (2022).
Wang, Y., Song, B., Wang, S., Chen, M., Xie, Y., Xiao, G., Wang, L. & Wang, T. Sprod for de-noising spatially resolved transcriptomics data based on position and image information. Nat. Methods 19, 950�C958 (2022).
Han, J. H., Kim, Y. K., Kim, H., Lee, J., Oh, M. J., Kim, S. B., Kim, M., Kim, K. H., Yoon, H. J., Lee, M.-S., Minna, J. D., White, M. A. & Kim, H. S. Snail acetylation by autophagy-derived acetyl-coenzyme A promotes invasion and metastasis of KRAS-LKB1 co-mutated lung cancer cells. Cancer Commun (Lond) 42, 716�C749 (2022).
Bartolacci, C., Andreani, C., Vale, G., Berto, S., Melegari, M., Crouch, A. C., Baluya, D. L., Kemble, G., Hodges, K., Starrett, J., Politi, K., Starnes, S. L., Lorenzini, D., Raso, M. G., Solis Soto, L. M., Behrens, C., Kadara, H., Gao, B., Wistuba, I. I., Minna, J. D., McDonald, J. G. & Scaglioni, P. P. Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer. Nat. Commun. 13, 4327 (2022).
DeBerardinis, R. J. & Keshari, K. R. Metabolic analysis as a driver for discovery, diagnosis, and therapy. Cell 185, 2678�C2689 (2022).
Muraki, N., Yamada, M., Doki, H., Nakai, R., Komeda, K., Goto, D., Kawabe, N., Matsuoka, K., Matsushima, M., Kawabe, T., Tanaka, I., Morise, M., Shay, J. W., Minna, J. D. & Sato, M. Resistance to mutant KRASV12-induced senescence in an hTERT/Cdk4-immortalized normal human bronchial epithelial cell line. Exp. Cell Res. 414, 113053 (2022).
Bajaj, R., Warner, A. N., Fradette, J. F. & Gibbons, D. L. Dance of the golgi: understanding golgi dynamics in cancer metastasis. Cells 11, (2022).
Kim, S. T., Chu, Y., Misoi, M., Suarez-Almazor, M. E., Tayar, J. H., Lu, H., Buni, M., Kramer, J., Rodriguez, E., Hussain, Z., Neelapu, S. S., Wang, J., Shah, A. Y., Tannir, N. M., Campbell, M. T., Gibbons, D. L., Cascone, T., Lu, C., Blumenschein, G. R., Altan, M., Lim, B., Valero, V., Loghin, M. E., Tu, J., Westin, S. N., Naing, A., Garcia-Manero, G., Abdel-Wahab, N., Tawbi, H. A., Hwu, P., Oliva, I. C. G., Davies, M. A., Patel, S. P., Zou, J., Futreal, A., Diab, A., Wang, L. & Nurieva, R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat. Commun. 13, 1970 (2022).
Meraz, I. M., Majidi, M., Shao, R., Meng, F., Ha, M. J., Shpall, E. & Roth, J. A. TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model. Commun. Biol. 5, 167 (2022).
�鶹ӳ��

Publications

2025

2024

2023

2022

Give Now

Research Areas

Subscribe
